This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
tim.hodson Mon, 03/10/2025 - 11:17 At the Cardiovascular Research Technologies (CRT) 2025 conference in Washington, D.C., The analysis of data from SCAARon the Prevail coronary paclitaxel drug-coated balloon (DCB) will be presented as a late-breaking clinical trial at Cardiovascular Research Technologies (CRT) 2025 in Washington, D.C.
Stroke, Volume 56, Issue 4 , Page e114-e118, April 1, 2025. Intracranial atherosclerotic stenosis is a leading cause of stroke with a significant risk of recurrent ischemic events despite aggressive medical management. However, 3 percutaneous angioplasty and stenting randomized trials showed negative or neutral results.
Stroke, Volume 56, Issue Suppl_1 , Page AWP252-AWP252, February 1, 2025. Baseline angiograms were reviewed to assess the presence or absence of intracranial stenosis lesions (IS+ Vs IS-) different than the target occlusion. Bailout strategies were required more often in the IS+ group (34.6% minutes; p=0.018). Vs 3; p=0.036).Conclusions:Our
Stroke, Volume 56, Issue Suppl_1 , Page ADP36-ADP36, February 1, 2025. All patients had headache, and funduscopic examination demonstrated papilledema for all patients. All patients had headache, and funduscopic examination demonstrated papilledema for all patients.
Stroke, Volume 56, Issue Suppl_1 , Page AWP286-AWP286, February 1, 2025. Background:Hemodynamic evaluation is crucial in assessing stroke risk in patients with symptomatic intracranial atherosclerotic stenosis (sICAS). before PTAS. before PTAS.
Stroke, Volume 56, Issue Suppl_1 , Page AWMP94-AWMP94, February 1, 2025. National Inpatient Sample (NIS) database from 2009 to 2020, evaluating patients who presented with stroke from ICAD and were treated with angioplasty and stenting and analyzed presenting co-morbidities and patient outcomes.
Stroke, Volume 56, Issue Suppl_1 , Page ATMP58-ATMP58, February 1, 2025. ml/h, P = 0.04), a higher likelihood of parent artery stenosis (65% vs. 20.8%, P < 0.001), and increased need for angioplasty or stenting (50% vs. 17%, P < 0.001). ml/h vs. 7.5 The mismatch group also had a higher DWIR% (37.7%
tim.hodson Mon, 03/10/2025 - 11:17 At the Cardiovascular Research Technologies (CRT) 2025 conference in Washington, D.C., The analysis of data from SCAARon the Prevail coronary paclitaxel drug-coated balloon (DCB) will be presented as a late-breaking clinical trial at Cardiovascular Research Technologies (CRT) 2025 in Washington, D.C.
Stroke, Volume 56, Issue Suppl_1 , Page ATMP10-ATMP10, February 1, 2025. Introduction:An optimal strategy for the treatment of intracranial atherosclerotic disease (ICAD) has remained unclear, despite medical therapy (antiplatelet therapy and LDL control management) or endovascular therapy (angioplasty or stenting).
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content